Corvus Pharma Presents Preclinical Data on Soquelitinib

Summary

Corvus Pharmaceuticals (NASDAQ: CRVS) presented preclinical data on soquelitinib for systemic sclerosis at the 2025 European Congress of Rheumatology (EULAR 2025) in Barcelona. The study results will be showcased in a poster presentation by Dr. Gonçalo Boleto from the Lisbon Academic Medical Centre, representing one of the top 10 abstracts selected by the Emerging EULAR Network (EMEUNET) made up of young rheumatologists and researchers.

Impact Analysis

The event is at the company level, as it involves Corvus Pharmaceuticals’ presentation of data on soquelitinib at a major rheumatology conference. This event could directly impact the company by influencing perceptions of its research progress and drug development pipeline. The presentation at EULAR 2025 may enhance Corvus’ visibility among medical professionals and potential investors, possibly affecting its stock price positively if the data is well-received. However, as the data is preclinical, there are inherent risks related to the drug’s future clinical development and regulatory approval processes.GlobeNewswire+ 3GlobeNewswire